Injectable risperidone shows effectiveness in first‐episode schizophrenia

In findings that conflict with those of other recent studies, a new 12‐month trial has found that long‐acting injectable risperidone was more effective than the oral formulation of the antipsychotic in controlling psychotic symptoms and preventing relapse in patients with recent onset of schizophrenia. The trial differed from other studies in that all patients in the comparison group received oral risperidone, rather than any one of a variety of oral antipsychotics.